Overview

Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery On Cardiopulmonary Bypass

Status:
Completed
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
A study to evaluate levosimendan compared with placebo in reducing the composite event rate of all-cause death, perioperative MI, need for new dialysis, or use of mechanical assist (IABP, LVAD or ECMO) in subjects with reduced ejection fraction undergoing cardiac surgery on cardiopulmonary bypass (CPB).
Phase:
Phase 3
Details
Lead Sponsor:
Tenax Therapeutics, Inc.
Treatments:
Simendan